Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a ...

Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high ...

Excluding these special items, adjusted loss per share was 72 cents compared with a loss of 85 cents per share in the ...

In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $55.00. Michael Ulz has given his ...

Ionis Pharmaceuticals Inc. ( (IONS) ) has released its Q3 earnings. Here is a breakdown of the information Ionis Pharmaceuticals Inc. presented ...

加利福尼亚州卡尔斯巴德 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)已确认计划于2025年上半年启动ION582的第三期研究,这是一种潜在的安格尔曼综合征 (AS)治疗方法。这一决定是在与美国食品和药物管理局 (FDA)成功会晤并就最终研究设计达成一致后做出的。

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 22.8% in the 3rd quarter, according to its most recent 13F filing ...

加利福尼亚州卡尔斯巴德 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)已收到美国食品和药物管理局(FDA)的确认,其新药申请(NDA)donidalorsen正在审核中。Donidalorsen是一种研究中的RNA靶向药物,旨在预防12岁及以上患者的遗传性血管性水肿(HAE)发作。 FDA已将处方药用户费法案(PDUFA)行动日期定为2025年8月21日。如 ...

Good morning, and welcome to the IONA's Third Quarter 2024 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Wade Walke ...

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to ...

Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Looking ahead, ...